AC Immune Ltd - Asset Resilience Ratio
AC Immune Ltd (ACIU) has an Asset Resilience Ratio of 40.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how AC Immune Ltd's Asset Resilience Ratio has changed over time. Check ACIU capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down AC Immune Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ACIU company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.63 Million | 40.48% |
| Total Liquid Assets | $55.63 Million | 40.48% |
Asset Resilience Insights
- Very High Liquidity: AC Immune Ltd maintains exceptional liquid asset reserves at 40.48% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
AC Immune Ltd Industry Peers by Asset Resilience Ratio
Compare AC Immune Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for AC Immune Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for AC Immune Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.89% | $64.69 Million | $154.43 Million | -14.07pp |
| 2024-12-31 | 55.96% | $129.21 Million | $230.91 Million | +42.53pp |
| 2023-12-31 | 13.43% | $24.55 Million | $182.81 Million | -35.51pp |
| 2022-12-31 | 48.94% | $91.00 Million | $185.94 Million | +4.57pp |
| 2021-12-31 | 44.37% | $116.00 Million | $261.44 Million | +17.14pp |
| 2020-12-31 | 27.23% | $65.00 Million | $238.74 Million | -4.52pp |
| 2019-12-31 | 31.75% | $95.00 Million | $299.25 Million | +16.48pp |
| 2018-12-31 | 15.26% | $30.00 Million | $196.56 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $132.01 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $156.10 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $79.93 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $30.30 Million | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more